M&As this week: Boston Scientific, Colfax, Mazor Robotics

23 November 2018 (Last Updated November 22nd, 2018 11:12)

Boston Scientific has agreed to acquire BTG for £3.3bn ($4.2bn) in cash.

Boston Scientific has agreed to acquire BTG for £3.3bn ($4.2bn) in cash.

Common shareholders of BTG will be paid 840 pence a share in cash, under the agreement.

The acquisition will add BTG’s three businesses, including interventional medicine to Boston Scientific’s portfolio, enhancing the company’s capabilities in the fields of cancer and pulmonary embolism.

BTG also has pharmaceutical and licensing businesses, in addition to the interventional medicine business.

Based in the US, Boston Scientific is a medical device manufacturing company, while BTG is a healthcare company based in the UK.

Colfax has signed an agreement to acquire DJO Global using funds managed by private equity group Blackstone for $3.15bn in cash.

The acquisition will diversify Colfax’s product portfolio and expand its growth by providing a new platform in the orthopaedic solutions market.

The transaction is expected to be closed in the first quarter of 2019.

“Mazor Robotics shareholders will obtain $58.50 per American Depository Share or $29.25 for each ordinary share in cash for a total value of $1.64bn.”

Colfax is a technology company, while DJO Global is a medical devices company. Both companies are based in the US.

Mazor Robotics has received shareholder approval for the definitive merger agreement with Medtronic.

Mazor Robotics shareholders will obtain $58.50 per American Depository Share or $29.25 for each ordinary share in cash for a total value of approximately $1.64bn after completion of the transaction.

Based in Israel Mazor Robotics, while Medtronic is in the US.

Altus Capital Partners has acquired ChoiceSpine in for an undisclosed sum.

The acquisition will enable ChoiceSpine to expand in new product verticals and offer solutions to the patients for spinal disorders treatment.

Altus is a private equity firm, while ChoiceSpine is a medical device company. Both parties are based in the US.

Navis Capital Partners will acquire Pemba Capital Partners-owned Device Technologies in an A$700m ($509m) deal.

The acquisition will be funded through Navis Capital’s Asia-based funds and is expected to close by the end of this year. Upon completion, Navis Capital is expected to expand Device Technologies’ business both locally and across Asia.

Navis Capital is a private equity firm, while Device Technologies is a medical device supplier. Both companies are based in Australia.